Health Care·Biotechnology·$3.7B
Tango Therapeutics I (TNGX) operates in the biotechnology sector, focusing on developing innovative therapies for cancer treatment. With a market cap of $4 billion, the company is part of a critical industry that aims to improve patient outcomes through advanced medical solutions.
Earnings Per Share (EPS)
EPS is a key indicator of the company's profitability and financial health, which investors closely watch.
Research and Development (R&D) Spending
R&D spending reflects the company's commitment to innovation and future growth potential, especially in the biotech field.
1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
3Q
EPS Beat Rate
63%
Avg EPS Surprise
+116.40%
Avg Stock Reaction
+1.21%
In Q4 2025, Tango Therapeutics reported an EPS of -$0.29, slightly beating expectations. The stock reacted positively, gaining over 36% the next day.
Management Promises & Guidance
Overall expectations for Tango Therapeutics are mixed, with investors keenly awaiting updates on clinical trials and financial performance. The company's history of beating EPS estimates adds a layer of optimism.
Bull Case
If Tango can demonstrate significant progress in its clinical trials and maintain or reduce its EPS losses, it could lead to a strong rally in the stock price.
Bear Case
Conversely, if the company fails to provide promising updates or reports larger-than-expected losses, it could lead to a sharp decline in investor confidence.
Earnings Per Share (EPS)
N/AEPS is a key indicator of the company's profitability and financial health, which investors closely watch.
Research and Development (R&D) Spending
N/AR&D spending reflects the company's commitment to innovation and future growth potential, especially in the biotech field.
Clinical Trial Updates
N/AUpdates on clinical trials can significantly impact investor sentiment and stock price, as they indicate progress in drug development.
The print will turn on these two things.
Q1
What are the latest developments in the ongoing clinical trials?
Updates on clinical trials can significantly affect the stock price and investor sentiment, as they indicate the potential for future drug approvals.
Q2
How much is the company planning to spend on R&D this quarter?
R&D spending is crucial for a biotech firm, and any changes could signal shifts in strategy or confidence in their pipeline.
Why consensus could be wrong
The Street may underestimate the potential impact of recent clinical trial advancements, which could lead to a more favorable outlook than currently anticipated.
Supporting Evidence
The company's recent trial results have shown promising efficacy that could exceed market expectations.
Historical data indicates that Tango has a strong track record of beating EPS estimates, suggesting potential upside.
Investors may be overlooking the strategic partnerships that could enhance R&D capabilities and accelerate drug development.
Key Risk
If clinical trial results come in significantly better than expected, it could shift the entire narrative around the company's growth potential.
Pre-commit to what would confirm each case.
The market is weighing the potential of Tango's drug pipeline against its financial performance, making this quarter critical for future investor confidence.
Bull Confirmed If
Demonstrating a significant reduction in EPS losses, ideally moving towards breakeven or profitability.
Bear Confirmed If
Reporting larger-than-expected EPS losses or setbacks in clinical trial progress.
Implied Move
±N/A
There is no available options market data to gauge investor sentiment ahead of the earnings report.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Tango beats expectations and raises guidance, history suggests a potential stock increase of around 0.09%, confirming bullish sentiment.
In-Line / Cautious
If results are in line with expectations but management provides cautious commentary, the stock may experience muted movement as investors reassess.
Miss
Should the company miss expectations, history suggests a potential decline of around 3.08%, as investors react negatively to disappointing news.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ENBRIDGE INC
May 8, 2026